Form 4: NewAmsterdam Pharma CFO Acquires 38,000 Restricted Stock Units

NewAmsterdam Pharma's Chief Financial Officer, Mayur Ian Somaiya, was granted 38,000 restricted stock units on January 7, 2025.

Summary

• Mayur Ian Somaiya, the Chief Financial Officer of NewAmsterdam Pharma Co N.V., acquired 38,000 restricted stock units (RSUs) on January 7, 2025.
• Each RSU represents a contingent right to receive one ordinary share of the company.
• The RSUs were granted with no consideration.
• The RSUs will vest in three equal installments, with one-third vesting on each of the first, second, and third anniversaries of the vesting start date.
• Vesting is contingent upon Mr. Somaiya's continued service with the company through each vesting date.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management interests with shareholders. There are no negative implications.

Positives

• The grant of RSUs aligns the CFO's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the CFO.

Risks

• The vesting of the RSUs is contingent on continued employment, which could be a risk if the CFO leaves the company before all RSUs vest.

Industry Context

The granting of restricted stock units is a common practice in the pharmaceutical industry to incentivize and retain key executives.

Comparison to Industry Standards

• The vesting schedule of one-third annually over three years is a typical vesting schedule for RSU grants in the pharmaceutical industry.
• Many comparable companies use similar equity-based compensation to align executive interests with shareholder value.

Stakeholder Impact

• Shareholders may view the RSU grant positively as it incentivizes the CFO to work towards long-term value creation.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

restricted stock units, RSU, insider trading, executive compensation, equity, NewAmsterdam Pharma, NAMS, Mayur Ian Somaiya, CFO